Anatara has taken a different tack post-trial results, while Chimeric is raising funds and Imugene proposes a share consolidation Heramed falls victim to US healthcare funding cuts D-Day looms for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results